Susquehanna International Group’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,018
| Closed | -$254K | – | 13133 |
|
|
2025
Q4 | $254K | Buy |
+14,018
| New | +$209K | ﹤0.01% | 10338 |
|
|
2025
Q2 | – | Sell |
-41,014
| Closed | -$244K | – | 12617 |
|
|
2025
Q1 | $244K | Buy |
+41,014
| New | +$358K | ﹤0.01% | 10524 |
|
|
2024
Q3 | – | Sell |
-14,455
| Closed | -$123K | – | 11926 |
|
|
2024
Q2 | $123K | Buy |
14,455
+13,649
| +1,693% | +$205K | ﹤0.01% | 10877 |
|
|
2024
Q1 | $14K | Sell |
806
-2,691
| -77% | -$47.8K | ﹤0.01% | 11879 |
|
|
2023
Q4 | $44.8K | Sell |
3,497
-5,057
| -59% | -$118K | ﹤0.01% | 11751 |
|
|
2023
Q3 | $316K | Buy |
8,554
+2,268
| +36% | +$101K | ﹤0.01% | 9228 |
|
|
2023
Q2 | $253K | Sell |
6,286
-2,582
| -29% | -$146K | ﹤0.01% | 9789 |
|
|
2023
Q1 | $643K | Buy |
8,868
+6,584
| +288% | +$639K | ﹤0.01% | 7957 |
|
|
2022
Q4 | $187K | Sell |
2,284
-6,749
| -75% | -$703K | ﹤0.01% | 10230 |
|
|
2022
Q3 | $854K | Buy |
9,033
+6,678
| +284% | +$750K | ﹤0.01% | 7046 |
|
|
2022
Q2 | $458K | Sell |
2,355
-2,336
| -50% | -$381K | ﹤0.01% | 8492 |
|
|
2022
Q1 | $1.09M | Sell |
4,691
-385
| -8% | -$123K | ﹤0.01% | 6887 |
|
|
2021
Q4 | $2M | Buy |
5,076
+925
| +22% | +$389K | ﹤0.01% | 5497 |
|
|
2021
Q3 | $1.86M | Buy |
4,151
+1,204
| +41% | +$431K | ﹤0.01% | 5995 |
|
|
2021
Q2 | $1.15M | Buy |
2,947
+534
| +22% | +$190K | ﹤0.01% | 7386 |
|
|
2021
Q1 | $866K | Buy |
2,413
+169
| +8% | +$74.7K | ﹤0.01% | 8100 |
|
|
2020
Q4 | $1.1M | Buy |
2,244
+636
| +40% | +$294K | ﹤0.01% | 6490 |
|
|
2020
Q3 | $521K | Buy |
1,608
+239
| +17% | +$81.4K | ﹤0.01% | 7576 |
|
|
2020
Q2 | $498K | Buy |
1,369
+95
| +7% | +$24K | ﹤0.01% | 7363 |
|
|
2020
Q1 | $271K | Buy |
1,274
+339
| +36% | +$108K | ﹤0.01% | 8170 |
|
|
2019
Q4 | $385K | Sell |
935
-1,473
| -61% | -$508K | ﹤0.01% | 7505 |
|
|
2019
Q3 | $850K | Sell |
2,408
-965
| -29% | -$360K | ﹤0.01% | 6057 |
|
|
2019
Q2 | $1.7M | Buy |
+3,373
| New | +$2.38M | ﹤0.01% | 4503 |
|
|
2018
Q3 | – | Sell |
-1,921
| Closed | -$1.88M | – | 9176 |
|
|
2018
Q2 | $1.76M | Buy |
+1,921
| New | +$2.06M | ﹤0.01% | 4227 |
|
|
2017
Q1 | – | Sell |
-737
| Closed | -$305K | – | 8906 |
|
|
2016
Q4 | $261K | Buy |
+737
| New | +$312K | ﹤0.01% | 8217 |
|
|
2015
Q4 | – | Sell |
-968
| Closed | -$732K | – | 9389 |
|
|
2015
Q3 | $761K | Buy |
+968
| New | +$1.18M | ﹤0.01% | 6293 |
|
|
2015
Q1 | – | Sell |
-368
| Closed | -$246K | – | 9383 |
|
|
2014
Q4 | $246K | Buy |
+368
| New | +$225K | ﹤0.01% | 8467 |
|
Other funds holding ATRA
RG
VCM
EC
Susquehanna International Group's ATRA Position: Q1 2026 in Review
Susquehanna International Group sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 14,018 shares — an estimated $254K sold.
Susquehanna International Group first reported a position in ATRA in Q4 2014 and held it in 27 quarters. The position peaked at $2M in Q4 2021. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.
- Susquehanna International Group reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 14,018 Atara Biotherapeutics shares in Q1 2026, an estimated $254K.
- Susquehanna International Group first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 27 quarters.
- Susquehanna International Group's Atara Biotherapeutics position peaked at $2M in Q4 2021.
- 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.